Online inquiry

IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7074MR)

This product GTTS-WQ7074MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FAP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001291807.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2191
UniProt ID Q12884
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10237MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ9714MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ10601MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ13075MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8746MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ4317MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ4237MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ2559MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW